Elevation Oncology reported a net loss per share of USD 0.82 in Q4 2022, missing analyst expectations by 5.1%. Net loss for the quarter increased significantly by 97.9% YoY to USD 19 million. Net losses for the full financial year 2022 also worsened by almost 2x YoY to USD 95.1 million. Elevation Oncology is a clinical-stage company that does not generate any drug sales.
The significant increase in net losses for Q4 2022 was mainly attributable to the increase in R&D expenses which rose by more than 2x YoY, primarily due to seribantumab manufacturing and clinical trial expenses. Further, administration costs increased by 17.6% to USD 4 million due to an increase in personnel costs.
The company expects to achieve a few milestones for 2023 which include: 1) plans to present preclinical proof-of-concept data of EO-3021 at a medical conference in 1H 2023 and 2) expects to initiate Phase I clinical trial of EO-3021 in the US in 2H 2023.
Cash and cash equivalents stood at USD 90.3 million at the end of December 2022, decreasing from USD 107.9 million in September 2022. It expects to extend its cash runway till 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.